Sridevi Kalidindi

Sridevi Kalidindi

Auto-generated profile, based on publicly available information

Sridevi Kalidindi

South London and Maudsley NHS Trust

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Health Technology Assessment
Verified
Journal Article
Closed access
RHRichard Ig Holt
Richard Ig Holt
DHDaniel Hind
Daniel Hind
RGRebecca Gossage-Worrall
Rebecca Gossage-Worrall
MBMichael J Bradburn
Michael J Bradburn
DSDavid Saxon
David Saxon
ANAlison Northern
Alison Northern
Background: Obesity is twice as common in people with schizophrenia as in the general population. The National Institute for Health and Care Excellence guidance recommends that people with psychosis or schizophrenia, especially those taking antipsychotics, be offered a healthy eating and physical activity programme by their mental health care provider. There is insufficient evidence to inform how these lifestyle services should be commissioned. Objectives: To develop a lifestyle intervention for people with first episode psychosis or schizophrenia and to evaluate its clinical effectiveness, cost-effectiveness, delivery and acceptability. Design: A two-arm, analyst-blind, parallel-group, randomised controlled trial, with a 1 : 1 allocation ratio, using web-based randomisation; a mixed-methods process evaluation, including qualitative case study methods and logic modelling; and a cost–utility analysis. Setting: Ten community mental health trusts in England. Participants: People with first episode psychosis, schizophrenia or schizoaffective disorder. Interventions: Intervention group: (1) four 2.5-hour group-based structured lifestyle self-management education sessions, 1 week apart; (2) multimodal fortnightly support contacts; (3) three 2.5-hour group booster sessions at 3-monthly intervals, post core sessions. Control group: usual care assessed through a longitudinal survey. All participants received standard written lifestyle information. Main outcome measures: The primary outcome was change in weight (kg) at 12 months post randomisation. The key secondary outcomes measured at 3 and 12 months included self-reported nutrition (measured with the Dietary Instrument for Nutrition Education questionnaire), objectively measured physical activity measured by accelerometry [GENEActiv (Activinsights, Kimbolton, UK)], biomedical measures, adverse events, patient-reported outcome measures and a health economic assessment. Results: The trial recruited 414 participants (intervention arm: 208 participants; usual care: 206 participants) between 10 March 2015 and 31 March 2016. A total of 341 participants (81.6%) completed the trial. A total of 412 participants were analysed. After 12 months, weight change did not differ between the groups (mean difference 0.0 kg, 95% confidence interval –1.59 to 1.67 kg; p = 0.964); physical activity, dietary intake and biochemical measures were unchanged. Glycated haemoglobin, fasting glucose and lipid profile were unchanged by the intervention. Quality of life, psychiatric symptoms and illness perception did not change during the trial. There were three deaths, but none was related to the intervention. Most adverse events were expected and related to the psychiatric illness. The process evaluation showed that the intervention was acceptable, with participants valuing the opportunity to interact with others facing similar challenges. Session feedback indicated that 87.2% of participants agreed that the sessions had met their needs. Some indicated the desire for more ongoing support. Professionals felt that the intervention was under-resourced and questioned the long-term sustainability within current NHS settings. Professionals would have preferred greater access to participants’ behaviour data to tailor the intervention better. The incremental cost-effectiveness ratio from the health-care perspective is £246,921 per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio from the societal perspective is £367,543 per QALY gained. Conclusions: Despite the challenges of undertaking clinical research in this population, the trial successfully recruited and retained participants, indicating a high level of interest in weight management interventions; however, the STEPWISE intervention was neither clinically effective nor cost-effective. Further research will be required to define how overweight and obesity in people with schizophrenia should be managed. The trial results suggest that lifestyle programmes for people with schizophrenia may need greater resourcing than for other populations, and interventions that have been shown to be effective in other populations, such as people with diabetes mellitus, are not necessarily effective in people with schizophrenia. Trial registration: Current Controlled Trials ISRCTN19447796. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 22, No. 65. See the NIHR Journals Library website for further project information.

1 December 2011 in Thorax
Verified
Journal Article
Open access
PDF file
SHS. Huq
S. Huq
DPD. Price
D. Price
SSS. Sureshkumar
S. Sureshkumar
SKS. Kalidindi
S. Kalidindi
MWM. Walshaw
M. Walshaw
JHJ. Hadcroft
J. Hadcroft
Background Sleep apnoea can result in traffic accidents, and the British Lung Foundation's (BLF) “Snoring and Sleep Apnoea” and the Driver and Vehicle Licensing Agency's (DVLA) “Think! Tiredness can kill” leaflets are commonly used to inform patients about this. We wished to assess the impact of such knowledge on the general understanding and motivation of patients undergoing formal assessment for sleep apnoea in a sleep clinic. Methods In a prospective survey, patients were provided with the above leaflets when they underwent the sleep study, and completed a structured questionnaire when attending the results clinic several weeks later. Results 125 consecutive patients (92 male) with a mean (SD) age of 51 (14) years, BMI of 33.6 (6.9) and Epworth Sleepiness Scale of 10 (6) completed the questionnaire. 51 (41%) were eventually diagnosed with significant obstructive sleep apnoea/hypopnoea syndrome (OSAHS) requiring referral for continuous positive airway pressure therapy. 105 patients (84%) read the BLF leaflet and 91 (87%) assumed they understood about sleep apnoea from it. 28 (27%) believed they had sleep apnoea, 26 (25%) believed they did not, while the remainder (48%) were unsure. Although 28 (27%) became more worried about themselves, 56 (53%) were more keen to undertake the tests but 5 (5%) were not. 92 participants (74%) were current drivers and 84 (91%) read the DVLA leaflet. Only 10 of these (12%) thought they might have a disorder that could impact on their driving abilities although 38 (45%) were concerned they might not be allowed to drive in future. However, only 4 (5%) were discouraged to undertake the tests because of this. Overall, most patients (80%) found these leaflets informative and easy to understand. Conclusions These leaflets appear to improve patients' understanding of OSAHS and its implications, particularly regarding driving. Although they can engender concern and anxiety among some, the majority of patients felt motivated to undertake the tests. Improving the level of patient education and awareness through such leaflets may positively influence their involvement in overall management, potentially improving compliance and outcomes in the long term.

12 August 2026
Verified
Book Chapter
Closed access
PDF file
KPKaran Panwar
Karan Panwar
SCSilvia Cirstea
Silvia Cirstea
SKSridevi Kalidindi
Sridevi Kalidindi
ACAshim Chakraborty
Ashim Chakraborty